医学
放射治疗
毒性
临床试验
肺癌
免疫疗法
肿瘤科
肺毒性
模式
内科学
癌症
重症监护医学
社会科学
社会学
作者
Mengqian Li,Lu Gan,Andrew Song,Jianxin Xue,You Lü
标识
DOI:10.1016/j.bbcan.2019.02.004
摘要
The combination of programmed cell death 1/programmed cell death ligand 1 blockade and thoracic radiotherapy has become the new standard of care in the treatment of locally advanced non-small-cell lung cancer. The information regarding the pulmonary safety of such therapy remains limited to mostly retrospective studies and case reports with a small portion of data from prospective clinical trials. By analyzing the underlying mechanisms of interactions between radiation and immunotherapy from preclinical data and summarizing safety data from relevant clinical studies with pulmonary toxicity, we believe that longer and rigorous follow-up is warranted, to determine if the combination of such modalities is appropriate for patients without risking undue toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI